



COPY OF PAPERS  
ORIGINALLY FILED

#6/SEP 1658  
1.5405  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher  
Ariel Fletcher

3/7/2002  
Date of Deposit

Applicant: Padidam, et al.

Serial No.: 09/622,500

Filed: August 17, 2000

Title: RESISTANCE IN PLANTS TO  
INFECTION BY ssDNA VIRUS USING  
INOVIRIDAE VIRUS ssDNA-BINDING  
PROTEIN, COMPOSITIONS AND  
METHODS OF USE

)  
) Group Art Unit: 1638  
)  
) Examiner: G. Helmer  
)

) Our Ref.: TSRI 615.1  
)  
)  
)  
)  
)  
)

RECEIVED  
MAR 22 2002  
TECH CENTER 1600/2900

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES (37 CFR \$1.821-1.825)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the enclosed copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR \$1.821-1.825 mailed February 12, 2002, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR \$1.821 - \$1.825. Also enclosed is the Sequence Listing in computer readable form, submitted as required by 37 CFR \$1.821(e), on which the Sequence Listing is labeled TSRI 615.1.

Applicants respectfully request entry of the Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer

readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

If there are any fees associated with this request, please charge our Deposit Account 19-0962.

March 07, 2002  
Date

Michael S. McCarthy  
Michael S. McCarthy, Reg No. 46,910

THE SCRIPPS RESEARCH INSTITUTE  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, California 92037  
(858) 784-2937



UNITED STATES PATENT AND TRADEMARK OFFICE

COPY OF PAPER  
ORIGINALLY FILED

RECEIVED

MAR 22 2002

TECH CENTER 1600/2900

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/622,500	08/17/2000	Malla Padidam	TSRI 615 I	8586

7590 02/12/2002  
The Scripps Research Institute  
10550 North Torrey Pines Road  
Mail Drop Tpc 8  
La Jolla, CA 92037

MAN 00067

EXAMINER

HELMER, GEORGIA L

ART UNIT

PAPER NUMBER

1638

DATE MAILED: 02/12/2002

DOCKETED  
2/20/02 AF  
Due: 3/12/02  
Final: 7/12/02

Please find below a communication from the EXAMINER in charge of this application  
Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.


Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to Georgia Helmer at telephone number (703)308-7023.

Phuong Bui  
PHUONG T. BUI 2/6/02  
PRIMARY EXAMINER

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18220, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7. Other: \_\_\_\_\_

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

MAR 22 2002

TECH CENTER 1600/2900

## Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
For CRF submission help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.